CCL3 and neoplasm: In addition, we have identified modulation of the fractalkine receptor CX3CR1 with E6130 and/or remodelling of the tumour chemokine profile with MIP-1α and RANTES as potential therapeutic approaches to limit NK cell migration towards omentum and augment NK cell migration towards OAC tumour.